- Conditions
- Colorectal Liver Metastases
- Interventions
- 5-Fluorouracil, Bevacizumab, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 1,005
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
- Interventions
- Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures, Cisplatin, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Interventions
- Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more
- Conditions
- Pancreatic Cancer
- Interventions
- dipyridamole, fluorouracil, leucovorin calcium, mitomycin C
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- Esophageal Carcinoma
- Interventions
- mFOLFOX6, Chemoradiation
- Drug · Combination Product
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- LEE011, Everolimus
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7
- Interventions
- Bevacizumab, Fluorouracil, Leucovorin Calcium, Oxaliplatin
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Paclitaxel, Eribulin, 5-Fluorouracil, Epirubicin, Cyclophosphamide, Doxorubicin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Resected Pancreatic Adenocarcinoma
- Interventions
- mFOLFIRINOX, Proton beam radiation
- Drug · Radiation
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- ASP2138, Oxaliplatin, Leucovorin, 5-FU, Irinotecan, Gemcitabine, Nab-paclitaxel, Capecitabine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Durham, North Carolina
- Conditions
- Esophageal Cancer
- Interventions
- cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- FOLFOX regimen, dexamethasone, floxuridine, fluorouracil, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- OT-101, mFOLFIRINOX
- Drug
- Lead sponsor
- Oncotelic Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Houston, Texas
- Conditions
- Neoplasms
- Interventions
- 5-FU, Docetaxel, Enzalutamide, Ipatasertib, Leucovorin, Oxaliplatin, Paclitaxel
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 7
- States / cities
- San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 4 more
- Conditions
- Advanced Solid Tumor Malignancies
- Interventions
- PD-0332991, 5-FU, Oxaliplatin
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Pancreatic Cancer
- Interventions
- Oxaliplatin, Irinotecan, Leucovorin, 5FU, Stereotactic Body Radiotherapy (SBRT)
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 4 more
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Interventions
- BOLD-100 +/- FOLFOX Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Drug
- Lead sponsor
- Bold Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Tampa, Florida
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
- Interventions
- FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Utidelone Capsule, Fluoropyrimidine- and Platinum-containing Therapy, Oxaliplatin, PD-1 inhibitor, Capecitabine
- Drug
- Lead sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
- Interventions
- Nab-paclitaxel 150 mg/m^2, Oxaliplatin 85 mg/m^2, 5-FU 1200 mg/m^2 x 2 D, Leucovorin 400 mg/m^2
- Drug
- Lead sponsor
- Al B. Benson, III, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Lake Forest, Illinois • Iowa City, Iowa + 4 more
- Conditions
- Gastric Adenocarcinoma
- Interventions
- Andecaliximab, Placebo, Leucovorin, 5-fluorouracil, Oxaliplatin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 31
- States / cities
- La Jolla, California • Los Angeles, California • Whittier, California + 27 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- fluorouracil, leucovorin calcium, oxaliplatin, irinotecan hydrochloride, bevacizumab, cetuximab, capecitabine, mutation analysis, gene expression analysis, laboratory biomarker analysis, immunohistochemistry staining method, nucleic acid sequencing, protein expression analysis, polymerase chain reaction, DNA analysis
- Drug · Biological · Genetic + 1 more
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
- Interventions
- EndoTAG-1, Gemcitabine
- Drug
- Lead sponsor
- SynCore Biotechnology Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 16
- States / cities
- Corona, California • Atlanta, Georgia • Columbus, Georgia + 12 more
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Interventions
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Drug
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Sunnyvale, California • New York, New York • Houston, Texas